Agendia Spotlights the Future of Personalized Breast Cancer Care at 2022 San Antonio Breast Cancer Symposium

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia, Inc., a leader in gene expression profiling for early-stage breast cancer, received acceptance for all six abstract submissions that will help guide the future of personalized cancer care and will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS). These studies focus on…